Biogen (BIIB)
Health Care · Biopharmaceutical - specialty therapeutics
Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease.
What Biogen does
Biogen discovers, develops, manufactures, and commercializes therapies for diseases in neurology, immunology, and rare genetic conditions. The company operates through a diversified portfolio of marketed products including multiple sclerosis treatments (TECFIDERA, AVONEX, TYSABRI), neurodegeneration therapies (LEQEMBI, SKYCLARYS), and specialty medicines. Biogen also maintains a pipeline of investigational products targeting conditions like ALS, Friedreich's ataxia, and lupus. The company operates globally with significant presence across the U.S., Europe, and other markets, relying on both internal R&D and strategic collaborations and acquisitions.
Themes: ["Alzheimer's disease and neurodegeneration","multiple sclerosis","spinal muscular atrophy","Friedreich's ataxia","ALS (amyotrophic lateral sclerosis)","rare genetic diseases","specialty immunology","antisense oligonucleotide platform","neurology pipeline","orphan diseases"]
Fundamentals
- Price$198.91 as of 2026-07-09 close
- Market cap$29.4B as of 2026-07-10
- 1-year return+49.5% as of 2026-07-09 close
- P/E21.42 as of 2026-07-10
- Net margin+13.8% as of 2026-07-10
- Gross margin+75.5% as of 2026-07-10
- ROE+7.5% as of 2026-07-10
- Debt / equity0.34 as of 2026-07-10
- Revenue growth (YoY)+1.2% as of 2026-07-10
- Revenue CAGR (3y)-0.9% SEC XBRL
- Beta0.15 as of 2026-07-10
Key risks (from latest filing)
["Competition from generic and biosimilar entrants for key marketed products (TECFIDERA generics, TYSABRI biosimilars) and new competing therapies eroding market share and pricing power","Substantial revenue dependence on anticipated timing and successful development of new products and additional indications, including LEQEMBI and SKYCLARYS, with regulatory approval and commercial execution uncertainty","Regulatory and reimbursement risks including unfavorable or delayed reimbursement decisions, coverage restrictions, pricing pressure from governments, and changes in third-party payer policies"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.